EyeGene Inc. (KOSDAQ:185490)

EyeGene Statistics

Total Valuation

EyeGene has a market cap or net worth of KRW 47.92 billion. The enterprise value is 24.43 billion.

Market Cap	47.92B
Enterprise Value	24.43B

Important Dates

The next estimated earnings date is Tuesday, March 17, 2026.

Earnings Date	Mar 17, 2026
Ex-Dividend Date	n/a

Share Statistics

EyeGene has 27.03 million shares outstanding. The number of shares has increased by 46.90% in one year.

Current Share Class	27.03M
Shares Outstanding	27.03M
Shares Change (YoY)	+46.90%
Shares Change (QoQ)	+0.01%
Owned by Insiders (%)	6.43%
Owned by Institutions (%)	n/a
Float	19.49M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	11.68
PB Ratio	1.04
P/TBV Ratio	1.23
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-2.53
EV / Sales	5.95
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-4.39

Financial Position

The company has a current ratio of 4.02, with a Debt / Equity ratio of 0.01.

Current Ratio	4.02
Quick Ratio	3.91
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.11
Interest Coverage	-12.41

Financial Efficiency

Return on equity (ROE) is -19.63% and return on invested capital (ROIC) is -10.80%.

Return on Equity (ROE)	-19.63%
Return on Assets (ROA)	-9.01%
Return on Invested Capital (ROIC)	-10.80%
Return on Capital Employed (ROCE)	-18.07%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	47
Asset Turnover	0.07
Inventory Turnover	5.63

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -40.34% in the last 52 weeks. The beta is 1.08, so EyeGene's price volatility has been similar to the market average.

Beta (5Y)	1.08
52-Week Price Change	-40.34%
50-Day Moving Average	2,283.14
200-Day Moving Average	2,848.04
Relative Strength Index (RSI)	28.69
Average Volume (20 Days)	316,294

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, EyeGene had revenue of KRW 4.10 billion and -9.67 billion in losses. Loss per share was -307.38.

Revenue	4.10B
Gross Profit	1.19B
Operating Income	-8.97B
Pretax Income	-9.74B
Net Income	-9.67B
EBITDA	-6.77B
EBIT	-8.97B
Loss Per Share	-307.38

Balance Sheet

The company has 26.25 billion in cash and 597.57 million in debt, giving a net cash position of 25.65 billion or 949.00 per share.

Cash & Cash Equivalents	26.25B
Total Debt	597.57M
Net Cash	25.65B
Net Cash Per Share	949.00
Equity (Book Value)	45.88B
Book Value Per Share	1,615.16
Working Capital	21.03B

Cash Flow

In the last 12 months, operating cash flow was -5.25 billion and capital expenditures -304.98 million, giving a free cash flow of -5.56 billion.

Operating Cash Flow	-5.25B
Capital Expenditures	-304.98M
Free Cash Flow	-5.56B
FCF Per Share	-205.70

Margins

Gross margin is 28.89%, with operating and profit margins of -218.51% and -235.54%.

Gross Margin	28.89%
Operating Margin	-218.51%
Pretax Margin	-237.39%
Profit Margin	-235.54%
EBITDA Margin	-165.07%
EBIT Margin	-218.51%
FCF Margin	n/a

Dividends & Yields

EyeGene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-46.90%
Shareholder Yield	-46.90%
Earnings Yield	-20.17%
FCF Yield	-11.60%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on June 28, 2021. It was a forward split with a ratio of 1.2.

Last Split Date	Jun 28, 2021
Split Type	Forward
Split Ratio	1.2

Scores

EyeGene has an Altman Z-Score of 0.28 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.28
Piotroski F-Score	2